Share-based Payment Arrangement, Expense of Mineralys Therapeutics, Inc. from 31 Mar 2022 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Mineralys Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2022 to 30 Sep 2025.
  • Mineralys Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $5,841,000, a 86% increase year-over-year.
  • Mineralys Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $17,173,000, a 78% increase year-over-year.
  • Mineralys Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $11,336,000, a 124% increase from 2023.
  • Mineralys Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5,060,000, a 1012% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Mineralys Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $17,173,000 $5,841,000 +$2,702,000 +86% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $14,471,000 $4,553,000 +$1,681,000 +59% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $12,790,000 $3,645,000 +$1,454,000 +66% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $11,336,000 $3,134,000 +$1,677,000 +115% 01 Oct 2024 31 Dec 2024 10-K 12 Feb 2025 2024 FY
Q3 2024 $9,659,000 $3,139,000 +$1,561,000 +99% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $8,098,000 $2,872,000 +$1,596,000 +125% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $6,502,000 $2,191,000 +$1,442,000 +193% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $5,060,000 $1,457,000 +$1,239,000 +568% 01 Oct 2023 31 Dec 2023 10-K 12 Feb 2025 2024 FY
Q3 2023 $3,821,000 $1,578,000 +$1,386,000 +722% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $2,435,000 $1,276,000 +$1,250,000 +4808% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $1,185,000 $749,000 +$730,000 +3842% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $455,000 $218,000 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $192,000 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $26,000 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $19,000 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1

Mineralys Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $11,336,000 +$6,276,000 +124% 01 Jan 2024 31 Dec 2024 10-K 12 Feb 2025 2024 FY
2023 $5,060,000 +$4,605,000 +1012% 01 Jan 2023 31 Dec 2023 10-K 12 Feb 2025 2024 FY
2022 $455,000 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.